Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia

This study has been completed.
Sponsor:
Information provided by:
Henry Ford Health System
ClinicalTrials.gov Identifier:
NCT00294502
First received: February 21, 2006
Last updated: NA
Last verified: September 2003
History: No changes posted
  Purpose

To study the efficacy of an antibacterial/anticoagulant solution instilled into the hemodialysis (HD) catheters after each treatment (“antibiotic lock solution - ALS”) to prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.


Condition Intervention Phase
ESRD
Drug: Gentamycin/citrate, Minocycline/EDTA
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Henry Ford Health System:

Primary Outcome Measures:
  • Incidence of symptomatic CRB

Estimated Enrollment: 120
Study Start Date: September 2003
Estimated Study Completion Date: May 2004
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • ESRD patients with tunnelled catheters

Exclusion Criteria:

  • patients on IV abx for infections, patients who have AV graft, AV fistulas
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00294502

Locations
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Investigators
Principal Investigator: Antanole Bearabe, MD Henry Ford Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00294502     History of Changes
Other Study ID Numbers: 3008
Study First Received: February 21, 2006
Last Updated: February 21, 2006
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Gentamicins
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 14, 2014